Metropolitan Life Insurance Company (MetLife)’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-5,541
| Closed | -$499K | – | 2644 |
|
|
2021
Q4 | $499K | Buy |
5,541
+425
| +8% | +$36.3K | 0.01% | 1433 |
|
|
2021
Q3 | $473K | Sell |
5,116
-168
| -3% | -$12.9K | 0.01% | 1504 |
|
|
2021
Q2 | $411K | Sell |
5,284
-190
| -3% | -$14.4K | 0.01% | 1648 |
|
|
2021
Q1 | $408K | Sell |
5,474
-246
| -4% | -$22.7K | 0.01% | 1539 |
|
|
2020
Q4 | $975K | Sell |
5,720
-44
| -0.8% | -$6.52K | 0.01% | 896 |
|
|
2020
Q3 | $809K | Sell |
5,764
-149
| -3% | -$22.6K | 0.01% | 870 |
|
|
2020
Q2 | $948K | Buy |
5,913
+966
| +20% | +$131K | 0.02% | 769 |
|
|
2020
Q1 | $484K | Sell |
4,947
-156
| -3% | -$17.8K | 0.01% | 1064 |
|
|
2019
Q4 | $658K | Sell |
5,103
-95
| -2% | -$9.59K | 0.01% | 1164 |
|
|
2019
Q3 | $392K | Buy |
5,198
+308
| +6% | +$36.4K | 0.01% | 1444 |
|
|
2019
Q2 | $743K | Sell |
4,890
-113
| -2% | -$13.7K | 0.01% | 1068 |
|
|
2019
Q1 | $596K | Sell |
5,003
-104
| -2% | -$13.4K | 0.01% | 1182 |
|
|
2018
Q4 | $557K | Buy |
5,107
+261
| +5% | +$32.6K | 0.01% | 1127 |
|
|
2018
Q3 | $783K | Sell |
4,846
-28
| -0.6% | -$3.83K | 0.01% | 1066 |
|
|
2018
Q2 | $644K | Sell |
4,874
-14,323
| -75% | -$1.35M | 0.01% | 1151 |
|
|
2018
Q1 | $1.42M | Buy |
19,197
+333
| +2% | +$22.2K | 0.02% | 729 |
|
|
2017
Q4 | $1.05M | Sell |
18,864
-20,529
| -52% | -$1.09M | 0.01% | 867 |
|
|
2017
Q3 | $1.79M | Buy |
39,393
+3,900
| +11% | +$156K | 0.01% | 975 |
|
|
2017
Q2 | $1.2M | Hold |
35,493
| – | – | 0.01% | 1144 |
|
|
2017
Q1 | $1.05M | Hold |
35,493
| – | – | 0.01% | 1211 |
|
|
2016
Q4 | $974K | Buy |
35,493
+3,717
| +12% | +$149K | 0.01% | 1306 |
|
|
2016
Q3 | $1.95M | Hold |
31,776
| – | – | 0.01% | 964 |
|
|
2016
Q2 | $606K | Hold |
31,776
| – | – | ﹤0.01% | 1565 |
|
|
2016
Q1 | $620K | Hold |
31,776
| – | – | ﹤0.01% | 1459 |
|
|
2015
Q4 | $1.23M | Buy |
31,776
+2,842
| +10% | +$92.1K | 0.01% | 1084 |
|
|
2015
Q3 | $929K | Sell |
28,934
-802
| -3% | -$27.2K | 0.01% | 1225 |
|
|
2015
Q2 | $905K | Sell |
29,736
-1,913
| -6% | -$39.1K | 0.01% | 1356 |
|
|
2015
Q1 | $420K | Hold |
31,649
| – | – | ﹤0.01% | 1647 |
|
|
2014
Q4 | $458K | Hold |
31,649
| – | – | ﹤0.01% | 1818 |
|
|
2014
Q3 | $668K | Hold |
31,649
| – | – | ﹤0.01% | 1527 |
|
|
2014
Q2 | $943K | Buy |
31,649
+620
| +2% | +$19.6K | 0.01% | 1395 |
|
|
2014
Q1 | $746K | Buy |
31,029
+970
| +3% | +$24.7K | 0.01% | 1544 |
|
|
2013
Q4 | $612K | Buy |
30,059
+2,815
| +10% | +$83.6K | ﹤0.01% | 1665 |
|
|
2013
Q3 | $1.29M | Hold |
27,244
| – | – | 0.01% | 1145 |
|
|
2013
Q2 | $1.04M | Buy |
+27,244
| New | +$974K | 0.01% | 1213 |
|
Other funds holding SRPT
ACA
EC
Metropolitan Life Insurance Company (MetLife)'s SRPT Position: Q1 2022 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 5,541 shares — an estimated $499K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in SRPT in Q2 2013 and held it in 35 quarters. The position peaked at $1.95M in Q3 2016. 329 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 5,541 Sarepta Therapeutics shares in Q1 2022, an estimated $499K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 35 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Sarepta Therapeutics position peaked at $1.95M in Q3 2016.
- 329 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.